Said Darwazah Buys 50,000 Shares of Hikma Pharmaceuticals Plc (HIK) Stock
Hikma Pharmaceuticals Plc (LON:HIK) insider Said Darwazah purchased 50,000 shares of the stock in a transaction that occurred on Monday, September 26th. The stock was bought at an average price of GBX 2,078 ($27.12) per share, with a total value of £1,039,000 ($1,356,219.81).
Said Darwazah also recently made the following trade(s):
- On Wednesday, September 28th, Said Darwazah purchased 10,000 shares of Hikma Pharmaceuticals Plc stock. The stock was bought at an average price of GBX 2,085 ($27.22) per share, with a total value of £208,500 ($272,157.68).
Hikma Pharmaceuticals Plc (LON:HIK) opened at 2049.00 on Friday. The company’s market cap is GBX 4.63 billion. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The firm has a 50-day moving average of GBX 2,176.69 and a 200-day moving average of GBX 2,245.79.
Several analysts have recently weighed in on HIK shares. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 2,550 ($33.29) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, August 16th. Barclays PLC restated an “overweight” rating and set a GBX 2,800 ($36.55) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 4th. Numis Securities Ltd started coverage on Hikma Pharmaceuticals Plc in a research note on Friday, July 22nd. They set an “add” rating and a GBX 2,830 ($36.94) target price for the company. Jefferies Group raised their target price on Hikma Pharmaceuticals Plc from GBX 2,380 ($31.07) to GBX 2,800 ($36.55) and gave the company a “buy” rating in a research note on Tuesday, July 5th. Finally, Morgan Stanley lowered their target price on Hikma Pharmaceuticals Plc from GBX 2,700 ($35.24) to GBX 2,500 ($32.63) and set an “equal weight” rating for the company in a research note on Friday, August 12th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of GBX 2,520.90 ($32.91).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.